Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ.

Semin Immunol. 2013 Apr;25(2):182-90. doi: 10.1016/j.smim.2013.04.008. Epub 2013 May 21. Review.

PMID:
23706598
2.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
3.

Current developments with peptide-based human tumor vaccines.

Khazaie K, Bonertz A, Beckhove P.

Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e. Review.

PMID:
19770763
4.

[Antitumor immunity and cellular cancer therapies].

Catros-Quemener V, Bouet F, Genetet N.

Med Sci (Paris). 2003 Jan;19(1):43-53. Review. French.

5.

Immunotherapy for pancreatic cancer: current concepts.

Kaufman HL, Di Vito J Jr, Hörig H.

Hematol Oncol Clin North Am. 2002 Feb;16(1):159-97, viii. Review.

PMID:
12063825
6.

Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.

Arens R.

Adv Immunol. 2012;114:217-43. doi: 10.1016/B978-0-12-396548-6.00009-3. Review.

PMID:
22449784
7.

Immune responses to human tumors: development of tumor vaccines.

Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS.

Anticancer Res. 2003 May-Jun;23(3A):1969-96. Review.

PMID:
12894571
8.

Myeloid-derived suppressor cells in cancer: recent progress and prospects.

Khaled YS, Ammori BJ, Elkord E.

Immunol Cell Biol. 2013 Sep;91(8):493-502. doi: 10.1038/icb.2013.29. Epub 2013 Jun 25. Review.

PMID:
23797066
9.

Immunotherapy of hepatocellular carcinoma.

Korangy F, Höchst B, Manns MP, Greten TF.

Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):345-53. doi: 10.1586/egh.10.18. Review.

PMID:
20528121
10.

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.

Lynch DH.

Immunol Rev. 2008 Apr;222:277-86. doi: 10.1111/j.1600-065X.2008.00621.x. Review.

PMID:
18364008
11.

Targeted therapies to improve tumor immunotherapy.

Begley J, Ribas A.

Clin Cancer Res. 2008 Jul 15;14(14):4385-91. doi: 10.1158/1078-0432.CCR-07-4804. Review.

12.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
13.

Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE.

Anticancer Res. 2000 Jul-Aug;20(4):2665-76. Review.

PMID:
10953341
14.
15.
16.

Combinatorial cancer immunotherapy.

Hodi FS, Dranoff G.

Adv Immunol. 2006;90:341-68. Review.

PMID:
16730268
17.

Strategies of tumor immune evasion.

Seliger B.

BioDrugs. 2005;19(6):347-54. Review.

PMID:
16392887
18.

Experimental vaccine strategies for cancer immunotherapy.

Chen CH, Wu TC.

J Biomed Sci. 1998 Jul-Aug;5(4):231-52. Review.

PMID:
9691216
19.

Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.

Aguilar LK, Guzik BW, Aguilar-Cordova E.

J Cell Biochem. 2011 Aug;112(8):1969-77. doi: 10.1002/jcb.23126. Review.

PMID:
21465529
20.

[Immune response and cancer].

El Hage F, Abouzahr-Rifai S, Meslin F, Mami-Chouaib F, Chouaib S.

Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558. Review. French.

Supplemental Content

Support Center